Regeneron Presents Eye Treatment Results With EYLEA HD at Vision Research Meeting
Regeneron Presents Eye Treatment Results With EYLEA HD at Vision Research Meeting
Regeneron 在視覺研究會議上展示使用 EYLEA HD 的眼部治療結果
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA HD (aflibercept) Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA (aflibercept) Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting from May 5 to 9 in Seattle.
Regeneron Pharmicals, Inc.（納斯達克股票代碼：REGN）今天宣佈公佈了8毫克EYLEA HD（aflibercept）注射液關鍵臨床項目的積極長期結果和亞組分析。這些演講是14份關於EYLEA HD和EYLEA（aflibercept）注射液2 mg的摘要的一部分，這些摘要將在5月5日至9日在西雅圖舉行的視覺與眼科學研究協會（ARVO）年會上分享。